Technology area: Biotechnology & Pharmaceuticals
35 pending office actions • 22 art units • 32 examiners • 0 of 35 (0%) have an AI response strategy ready • 25 patents granted in the last 365 days
Janssen Pharmaceutica NV has 35 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 33 distinct examiners and 23 distinct art units, reflecting a large and distributed prosecution operation with repeated examiner and unit assignments.
ROZOF, TIMOTHY R is the busiest examiner, with 2 pending matters. That concentration is limited relative to the overall docket, so a centralized portfolio strategy should be paired with application-level review. The repeated use of art units creates an opportunity to track recurring examination issues, while examiner-specific response histories remain important for active matters.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (11%) |
| §103 only | 4 (11%) |
| §102 only | 2 (6%) |
| §112 only | 7 (20%) |
| Double-patenting only | 2 (6%) |
| Double-patenting + other | 5 (14%) |
| Multi-statute (no §101) | 10 (29%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ, RAYNA B | 2 | 33.6% | +19.2% |
| ROZOF, TIMOTHY R | 2 | 72.7% | +23.3% |
| BOATENG, AFUA BAMFOAA | 2 | 46.7% | +64.5% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.7% |
| LEESER, ERICH A | 1 | 81.9% | +13.3% |
| SCHMIDT, EMILY LOUISE | 1 | 58.4% | +36.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18863744 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | OH, TAYLOR V | — |
| 18763484 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | LEESER, ERICH A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17616248 | NOVEL SPIROBICYCLIC INTERMEDIATES | MCMILLIAN, KARA RENITA | 42d overdue |
| 17998204 | PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB | RICCI, CRAIG D | 3d overdue |
| 18004464 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 13d |
| 18837469 | EXPRESSION SYSTEMS FOR THE ALPHA6-CONTAINING NICOTINIC ACETYLCHOLINE RECEPTOR AND METHODS OF USE THEREOF | JOHNSON, ALLISON MARIE | — |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | WANG, CHANG YU | — |
| 18433053 | GENE THERAPY VECTORS FOR USE IN PARKINSON'S DISEASE | QIAN, CELINE X | — |
| 18429778 | Combination Therapy For Prostate Cancer | RODRIGUEZ, RAYNA B | — |
| 18570727 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | COPPINS, JANET L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004464 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 13d |
| 18649184 | COMPOUNDS AND USES THEREOF | ROZOF, TIMOTHY R | 26d |
| 18863675 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | BARSKY, JARED | — |
| 18863744 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | OH, TAYLOR V | — |
| 18799339 | Combination Therapy For Prostate Cancer | RODRIGUEZ, RAYNA B | — |
| 18837469 | EXPRESSION SYSTEMS FOR THE ALPHA6-CONTAINING NICOTINIC ACETYLCHOLINE RECEPTOR AND METHODS OF USE THEREOF | JOHNSON, ALLISON MARIE | — |
| 18834185 | ANTAGONIST OF ADENOSINE RECEPTORS | CHICKS, ASHLI ARIANA | — |
| 18787713 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | RAMACHANDRAN, UMAMAHESWARI | — |
| Art Unit | Apps |
|---|---|
| 1625 | 4 |
| 1628 | 4 |
| 3783 | 3 |
| 1627 | 2 |
| 1621 | 2 |
| 1623 | 2 |
| 3785 | 2 |
| 1617 | 2 |
| 1629 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18863675 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | BARSKY, JARED | 1629 | §112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18863744 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | OH, TAYLOR V | 1625 | §112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 18799339 | Combination Therapy For Prostate Cancer | RODRIGUEZ, RAYNA B | 1628 | §112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18837469 | EXPRESSION SYSTEMS FOR THE ALPHA6-CONTAINING NICOTINIC ACETYLCHOLINE RECEPTOR AND METHODS OF USE THEREOF | JOHNSON, ALLISON MARIE | 1638 | §101§103§112 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18834185 | ANTAGONIST OF ADENOSINE RECEPTORS | CHICKS, ASHLI ARIANA | 1626 | §112 | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18787713 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | RAMACHANDRAN, UMAMAHESWARI | 1627 | DP | Non-Final OA | — | Pending | Jul 29, 2024 |
| 18763484 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | LEESER, ERICH A | 1622 | DP | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18651946 | PRE-FILLED SYRINGE WITH OPTIMIZED STOPPER PLACEMENT | SCHMIDT, EMILY LOUISE | 3783 | §103 | Non-Final OA | — | Pending | May 01, 2024 |
| 18649184 | COMPOUNDS AND USES THEREOF | ROZOF, TIMOTHY R | 1625 | §102 | Final Rejection | 26d | Pending | Apr 29, 2024 |
| 18649114 | COMPOUNDS AND USES THEREOF | ROZOF, TIMOTHY R | 1625 | §102 | Final Rejection | — | Pending | Apr 29, 2024 |
| 18627010 | BLOOD-BASED ASSAY FOR DETECTING TAUOPATHY OR AMYLOIDOGENIC DISEASE | WANG, CHANG YU | 1675 | §101§102§112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18433053 | GENE THERAPY VECTORS FOR USE IN PARKINSON'S DISEASE | QIAN, CELINE X | 1637 | §101§102§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18429778 | Combination Therapy For Prostate Cancer | RODRIGUEZ, RAYNA B | 1628 | §103§112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18580583 | TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH NIRAPARIB | MAYHEW, BRADLEY SCOTT | 1621 | §102§103DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18570727 | (R)-N-ETHYL-5-FLUORO-N-ISOPROPYL-2-((5-(2-(6-((2-METHOXYETHYL)(METHYL)AMINO)-2-METHYLHEXAN-3-YL)-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-1,2,4-TRIAZIN-6-YL)OXY)BENZAMIDE BESYLATE SALT | COPPINS, JANET L | 1628 | §101§112DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18566249 | PYRIDAZINES OR 1,2,4-TRIAZINES SUBSTITUTED BY SPIROCYCLIC AMINES | SZNAIDMAN, MARCOS L | 1628 | §102§112DP | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18515672 | SYNTHESIS OF A CYCLIC PEPTIDE | KATAKAM, SUDHAKAR | 1658 | §103Other | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18560233 | COMBINATION THERAPIES | KENYON, JOHN S | 1625 | §103§112DP | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18560242 | COMBINATION THERAPIES | MCINTOSH III, TRAVISS C | 1693 | §112Other | Final Rejection | 9d | Pending | Nov 10, 2023 |
| 18559689 | Substituted Spiro Derivatives | HIRAKIS, SOPHIA P | 1623 | §112 | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18549638 | TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | ROMERO, KRISTEN WANG | 1624 | §112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18034890 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | HEITMEIER, KENDALL NICOLE | 1621 | §102§112 | Non-Final OA | — | Pending | May 02, 2023 |
| 18140344 | Suppression of Microglial Activation with Innate Lymphoid Cells | SAOUD, CHRISTINE J | 1646 | §103 | Non-Final OA | — | Pending | Apr 27, 2023 |
| 18024100 | DRUG DELIVERY DEVICES WITH MULTIPLE DRUG VIALS | VO, TU A | 3785 | §102§112 | Non-Final OA | — | Pending | Mar 01, 2023 |
| 18023643 | DRUG DELIVERY DEVICES WITH A MULTI-DISPENSING HEAD | ZIEGLER, MATTHEW D | 3785 | §103 | Non-Final OA | 40d | Pending | Feb 27, 2023 |
| 18023622 | DRUG DELIVERY DEVICES WITH PROPELLANT | STIMPERT, PHILIP EARL | 3783 | §102§103 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18022917 | DRUG DELIVERY DEVICES WITH A MECHANICAL STOP | DIOP, FATIMATA SAHRA | 3783 | §102§103§112 | Non-Final OA | — | Pending | Feb 23, 2023 |
| 18154020 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | ALLEN, MARIANNE P | 1647 | §112DP | Final Rejection | 181d overdue | Pending | Jan 12, 2023 |
| 18004464 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 1617 | §103§112Other | Final Rejection | 13d | Pending | Jan 06, 2023 |
| 18004477 | LONG-ACTING FORMULATIONS | PRAGANI, RAJAN | 1614 | §103§112Other | Final Rejection | — | Pending | Jan 06, 2023 |
| 18004336 | LONG-ACTING FORMULATIONS | BOATENG, AFUA BAMFOAA | 1617 | §103DP | Final Rejection | — | Pending | Jan 05, 2023 |
| 18084092 | BI-Heteroaryl Substitute 1,4-Benzodiazepines And Uses Thereof For The Treatment Of Cancer | HERNANDEZ, JACKSON J | 1627 | Other | Final Rejection | 14d | Pending | Dec 19, 2022 |
| 17998204 | PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB | RICCI, CRAIG D | 1611 | §103§112Other | Final Rejection | 3d overdue | Pending | Nov 08, 2022 |
| 17997435 | METHODS OF IDENTIFYING MODULATORS OF THE IL-17 PATHWAY | EVANS, CHRISTOPHER RYAN | 1677 | §102§103 | Non-Final OA | — | Pending | Oct 28, 2022 |
| 17616248 | NOVEL SPIROBICYCLIC INTERMEDIATES | MCMILLIAN, KARA RENITA | 1623 | §102§103§112Other | Non-Final OA | 42d overdue | Pending | Dec 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJanssen Pharmaceutica NV has 35 pending office actions as of October 2026, spread across 22 art units and 32 examiners.
Rayna B Rodriguez has the most, with 2 of Janssen Pharmaceutica NV's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
